New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
05:53 EDTQUREuniQure, Medison sign Glybera distribution agreement for Israel
uniQure N.V. and Medison Pharma announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency, or LPLD, in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
13:44 EDTQURE to host investor day
Subscribe for More Information
October 5, 2015
10:19 EDTQURESpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
September 28, 2015
09:19 EDTQUREuniQure weakness creates buying opportunity, says Roth Capital
Noting that uniQure has sold off amid worries about the high cost of its gene therapy, Roth Capital says that uniQure's gene therapy is less costly than the current lifetime treatment regimen for hemophiliacs. The firm thinks that the sell-off in the stock has created a buying opportunity for long-term investors. It keeps a $38 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use